

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVARTIS GENE THERAPIES, INC. & NOVARTIS PHARMACEUTICALS
CORPORATION,
Petitioners,

v.

GENZYME CORPORATION,
Patent Owner.

IPR2023-01045
Patent No. 10,429,288

**PATENT OWNER'S MANDATORY NOTICES
PURSUANT TO 37 C.F.R. § 42.8**

Pursuant to 37 C.F.R. § 42.8, Patent Owner, Genzyme Corporation, submits the following updates to its Mandatory Notices.

I. Real Party-In-Interest Under 37 § 42.8(a)(1)

Patent Owner Genzyme Corporation is a direct wholly-owned subsidiary of Aventis Inc. Genzyme Corporation and Aventis Inc. are indirect wholly-owned subsidiaries of Sanofi. Sanofi, the ultimate parent company of Genzyme Corporation, Genzyme Corporation, and Aventis, Inc. are the real parties-in-interest as Patent Owner.

II. Related Matter

In accordance with 37 C.F.R. § 42.8(b)(2), U.S. Patent No. 10,429,288 (the “288 patent”) is the subject of the following judicial matter that may affect, or be affected by, a decision in the following proceedings:

- a. Genzyme Corporation and Aventis Inc. v. Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation, Case No. 1:23-cv-00554-RGA, (D. Del), filed May 19, 2023; and
- b. Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation, IPR2023-01044 (PTAB), filed June 30, 2023.

III. Designation of Lead and Back-Up Counsel

Patent Owner adds as lead counsel Amanda K. Antons; Reg. No. 65,236. Patent Owner also adds as backup counsel Blaine M. Hackman, Reg. No. 67,479, and Katherine A. Helm (*pro hac vice* to be applied for).

In accordance with 37 C.F.R. § 42.8(b)(3), Patent Owner identifies the following designation of counsel:

Lead Counsel	Back-Up Counsel
Amanda K. Antons, Reg. No. 65,236 Dechert LLP 33 W. Wacker Dr. Suite 3400 Chicago, IL 60601 Tel: 312-646-5800 Fax: 312-646-5858 amanda.antons@dechert.com	Katherine A. Helm (<i>pro hac vice</i> to be applied for) Dechert LLP Three Bryant Park 1095 Avenue of the Americas New York, NY 10036-6797 Tel: 212-698-3500 Fax: 212-698-3599 Khelm@dechert.com Blaine Hackman, Reg. No. 67,479 Dechert LLP Three Bryant Park 1095 Avenue of the Americas New York, NY 10036-6797 Tel: 212-698-3500 Fax: 212-698-3599 blaine.hackman@dechert.com

IV. Service Information

Pursuant to 37 C.F.R. § 42.8(b)(4), Patent Owner may be served at the above addresses for lead and back-up counsel and “Zolgensma-Dechert-AllIPRs@dechert.com”. Pursuant to 37 C.F.R. § 42.6(e)(1), Patent Owner consents to electronic service by email.

Respectfully submitted,

Dated: July 11, 2023

/ Amanda K Antons/
Amanda K. Antons Reg. No. 65,236
Dechert LLP
33 W. Wacker Dr.
Suite 3400
Chicago, IL 60601
Tel: 312-646-5800
amanda.antons@dechert.com

Counsel for Patent Owner
Genzyme Corporation

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that today in

Novartis Gene Therapies, Inc. et al., v. Genzyme Corporation, IPR2023-01045

I caused to be served a copy of:

Patent Owner's Mandatory Notices Pursuant to 37 C.F.R. § 42.8

upon:

Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation c/o:

john.livingstone@finnegan.com

jeffrey.smyth@finnegan.com

amanda.murphy@finnegan.com

via:

electronic service to the email addresses above.

Dated: July 11, 2023

/Amanda K. Antons/

Amanda K. Antons Reg. No. 65,236

Dechert LLP

33 W. Wacker Dr.

Suite 3400

Chicago, IL 60601

Tel: 312-646-5800

amanda.antons@dechert.com

Counsel for Patent Owner

Genzyme Corporation